|
|
|
|
|
|
|
|
|
|
|
09.05.25 - 23:36
|
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025.
The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $12.04, the closing price of Delcath's common stock on April 30, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equa...
|
|
|
|
|
|
|
08.05.25 - 13:36
|
Delcath Systems Reports First Quarter 2025 Results and Business Highlights (Business Wire)
|
|
|
Conference Call Today at 8:30 a.m. Eastern Time
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.
First Quarter 2025 Financial Results
Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024
HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024
CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024
Gross margins of 86%, compared to 71% in the first quarter of 2024
Net income of $1.1 million, compared to a net loss of $11.1 million in the same quarter of 2024
Non-GAAP positive adjusted EBITDA in the first quarter of $7.6 million, compared to a loss of $7.3 million in the first quarter of 2024
Cash and investments of $58.9 million as of March ...
|
|
|
|
|
27.03.25 - 21:48
|
Beta Bionics Announces Board Appointment of Gerard Michel (GlobeNewswire EN)
|
|
|
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company....
|
|
|
|
|
|
|
14.03.25 - 21:06
|
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in January and February of 2025.
The grants resulted in the right to purchase 264,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The options were granted on February 28, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $14.17, the closing price of Delcath's common stock on February 28, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting...
|
|
|
|
|
|
|
|
|
06.03.25 - 14:03
|
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
|
|
|
Conference Call Today at 8:30 a.m. Eastern Time
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024.
Fourth Quarter and Full Year 2024 Financial Results
Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively
HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively
CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively
Gross margins of 86% for the fourth quarter and 83% for the full year
Fourth quarter and full year net loss of $3.4 million and $26.4 million, respectively
Non-GAAP positive adjusted EBITDA for the fourth quarter of $4.6 million and full year adjusted EBITDA loss of $2.5 million
During the year...
|
|
|
|
|
20.02.25 - 14:33
|
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 6, 2025, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2024.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.
Event Date: Thursday, March 6, 2025
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-877-407-3982
International: 1-201-493-6780
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1706497&tp_key=9763647546
A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
